How to buy Kintara Therapeutics stock - 17 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kintara Therapeutics stock

Own Kintara Therapeutics stock in just a few minutes.

Kintara Therapeutics, Inc is a biotechnology business based in the US. Kintara Therapeutics shares (KTRA) are listed on the NASDAQ and all prices are listed in US Dollars. Kintara Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of USD$48.1 million.

How to buy shares in Kintara Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Kintara Therapeutics. Find the stock by name or ticker symbol: KTRA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kintara Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Kintara Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Kintara Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Kintara Therapeutics share price

Use our graph to track the performance of KTRA stocks over time.

Kintara Therapeutics shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$0.5011 - USD$3.35
50-day moving average USD$1.9234
200-day moving average USD$1.6817
Wall St. target priceUSD$5.81
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Kintara Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kintara Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kintara Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -60.25%
Return on equity TTM -266.29%
Profit margin 0%
Book value N/A
Market capitalisation USD$48.1 million

TTM: trailing 12 months

Shorting Kintara Therapeutics shares

There are currently 613,290 Kintara Therapeutics shares held short by investors – that's known as Kintara Therapeutics's "short interest". This figure is 32.9% down from 914,634 last month.

There are a few different ways that this level of interest in shorting Kintara Therapeutics shares can be evaluated.

Kintara Therapeutics's "short interest ratio" (SIR)

Kintara Therapeutics's "short interest ratio" (SIR) is the quantity of Kintara Therapeutics shares currently shorted divided by the average quantity of Kintara Therapeutics shares traded daily (recently around 354502.89017341). Kintara Therapeutics's SIR currently stands at 1.73. In other words for every 100,000 Kintara Therapeutics shares traded daily on the market, roughly 1730 shares are currently held short.

However Kintara Therapeutics's short interest can also be evaluated against the total number of Kintara Therapeutics shares, or, against the total number of tradable Kintara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kintara Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Kintara Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0203% of the tradable shares (for every 100,000 tradable Kintara Therapeutics shares, roughly 20 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kintara Therapeutics.

Find out more about how you can short Kintara Therapeutics stock.

Kintara Therapeutics share dividends

We're not expecting Kintara Therapeutics to pay a dividend over the next 12 months.

Have Kintara Therapeutics's shares ever split?

Kintara Therapeutics's shares were split on a 1:10 basis on 7 May 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kintara Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Kintara Therapeutics shares which in turn could have impacted Kintara Therapeutics's share price.

Kintara Therapeutics share price volatility

Over the last 12 months, Kintara Therapeutics's shares have ranged in value from as little as $0.5011 up to $3.35. A popular way to gauge a stock's volatility is its "beta".

KTRA.US volatility(beta: 1.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kintara Therapeutics's is 1.5383. This would suggest that Kintara Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Kintara Therapeutics overview

Kintara Therapeutics, Inc. , a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site